Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Arrowhead's subsidiary Visirna has entered an agreement with Sanofi for plozasiran, a potential treatment for hypertriglyceridemia.

The deal with Arrowhead's Visirna Therapeutics subsidiary – which also includes $265 million in milestones tied to potential ...

Over 60% of patients who received ervogastat plus clesacostat for 48 weeks achieved MASH resolution without fibrosis ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Get the latest Plus Therapeutics, Inc. (PSTV) stock news and headlines to help you in your trading and investing decisions.

Bicycle Therapeutics picks up speed with £40m fundraisingUK biotech Bicycle Therapeutics has raised £40 million ($52m) in a new funding round to help it progress its pipeline, including its lead ...

Discover real-time Structure Therapeutics Inc. American Depositary Shares (GPCR) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead ...